Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Mymetics
Mymetics
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
Mymetics-led consortium awarded €8.4m to develop thermo stable and cold-chain independent vaccines
Virosome vaccine technology and HIV vaccine candidate to be used to develop scalable manufacturing process within 3.5 years
Research & Development
Mymetics to advance development of virosome-based malaria vaccine candidate
In partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the NIH
Research & Development
Mymetics’ HIV vaccine candidate to begin study at Texas Biomedical Research Institute
Follows a successfully completed smaller study at the Institute of Laboratory Animal Science (ILAS)
Research & Development
Astellas forms partnership with ClearPath to build vaccine portfolio
In-license vaccine technology for Respiratory Syncytial Virus (RSV) from Mymetics
Research & Development
Mymetics announces change of directors and management
Will explore a number of strategic opportunities for its HIV, RSV and other vaccine candidates
Pharmaceutical
Mymetics makes two appointments
New president and ceo and chairman
Subscribe now